A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies - Concepedia

Concepedia

Publication | Open Access

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

DOI Full Paper Access

40

Citations

21

References

2015

Year

Walter Cacciavillano, Claudia Sampor, Cecilia Venier, Mariano R. Gabri, María Teresa García de Dávila, Laura Galluzzo, Marcelo D. Guthmann, Leonardo Fainboim, Daniel F. Alonso, Guillermo Chantada

Pediatric Blood & Cancer

Abstract

Racotumomab vaccination has a favorable toxicity profile up to a dose of 0.4 mg, and most patients elicited an immune response. Its activity as immunotherapy for neuroectodermal malignancies will be tested in further clinical trials.

References

	Year	Citations

Page 1